PRESS RELEASE PRINCETON, N.J.—-Bristol-Myers Squibb Organization today announced essential next methods in the evolution of the organization’s R&D firm, including plans to expand its presence within hubs of scientific excellence and advancement with the opening of a fresh state-of-the-art analysis site in Cambridge, Mass. As well as the ongoing growth of the business’s R&D Discovery site in the San Francisco Bay Area. The new facility in Cambridge, which will be located at 100 Binney Road in Kendall Square, is normally likely to open in 2018. The ongoing site growth in the San Francisco Bay Area adds 61,000 square foot of laboratory and work place at the Woodside Technology Recreation area life research campus and is expected to be completed in 2016. In keeping with evolution of the R&D company’s strategic concentrate, that was announced in 2013 previously, today its plans to discontinue discovery study efforts in virology the company also announced.The analysis appeared online in the Annals of the Rheumatic Diseases. It was the first study to examine, in a population-structured study, the chance of fractures in childhood arthritis patients. Juvenile idiopathic arthritis , called juvenile rheumatoid arthritis also, is the most common pediatric rheumatic disease, influencing one in 1 approximately,000 U.S. Children. It was currently known that low bone mass occurs in patients with JIA, because of risk elements such as chronic swelling, delayed puberty, malnutrition, weakness, inactivity and treatment with steroid medications.